Phase I trial of temsirolimus (TEM) and perifosine (PER) for recurrent or progressive malignant glioma (MG).
Thomas Joseph Kaley
No relevant relationships to disclose
Elena Pentsova
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
No relevant relationships to disclose
Ingo K. Mellinghoff
No relevant relationships to disclose
Craig Nolan
No relevant relationships to disclose
Igor T. Gavrilovic
No relevant relationships to disclose
Lisa Marie DeAngelis
No relevant relationships to disclose
Mario E. Lacouture
No relevant relationships to disclose
Eric C. Holland
No relevant relationships to disclose
Andrew B. Lassman
Consultant or Advisory Role - Abbott Laboratories; CampusBio; Genentech; Kyowa Hakko Kirin; Merck; Novartis; RadMD; Roche
Honoraria - Merck
Research Funding - Agenus; AstraZeneca; Boehringer Ingelheim; Celldex; Genentech; MedImmune; Merck; NCI; Northwest Biotherapeutics; Novocure; Pfizer
Other Remuneration - Abbott Laboratories; CampusBio; Genentech; Kyowa Hakko Kirin; Merck; Novartis; RadMD; Roche